569 related articles for article (PubMed ID: 20001492)
1. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
[TBL] [Abstract][Full Text] [Related]
2. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
Samtani MN; Gopal S; Gassmann-Mayer C; Alphs L; Palumbo JM
CNS Drugs; 2011 Oct; 25(10):829-45. PubMed ID: 21936586
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.
Hough D; Lindenmayer JP; Gopal S; Melkote R; Lim P; Herben V; Yuen E; Eerdekens M
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(6):1022-31. PubMed ID: 19481579
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
Pandina GJ; Lindenmayer JP; Lull J; Lim P; Gopal S; Herben V; Kusumakar V; Yuen E; Palumbo J
J Clin Psychopharmacol; 2010 Jun; 30(3):235-44. PubMed ID: 20473057
[TBL] [Abstract][Full Text] [Related]
5. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
7. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia.
Cleton A; Rossenu S; Crauwels H; Berwaerts J; Hough D; Gopal S; Eerdekens M; Vandebosch A; Remmerie B; De Meulder M; Rosso CM
J Clin Pharmacol; 2014 Sep; 54(9):1048-57. PubMed ID: 24676998
[TBL] [Abstract][Full Text] [Related]
8. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
9. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
10. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.
Pandina G; Lane R; Gopal S; Gassmann-Mayer C; Hough D; Remmerie B; Simpson G
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):218-26. PubMed ID: 21092748
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.
Gopal S; Hough DW; Xu H; Lull JM; Gassmann-Mayer C; Remmerie BM; Eerdekens MH; Brown DW
Int Clin Psychopharmacol; 2010 Sep; 25(5):247-56. PubMed ID: 20389255
[TBL] [Abstract][Full Text] [Related]
12. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
[TBL] [Abstract][Full Text] [Related]
13. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.
Owen RT
Drugs Today (Barc); 2010 Jul; 46(7):463-71. PubMed ID: 20683501
[TBL] [Abstract][Full Text] [Related]
14. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L
Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628
[TBL] [Abstract][Full Text] [Related]
15. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
[TBL] [Abstract][Full Text] [Related]
16. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
[TBL] [Abstract][Full Text] [Related]
19. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.
Samtani MN; Vermeulen A; Stuyckens K
Clin Pharmacokinet; 2009; 48(9):585-600. PubMed ID: 19725593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
